Preparations to prescribe`tumor-agnostic' anticancer drugs in the field are well underway.

According to industry sources, Bayer Korea’s neurotrophic tyrosine receptor kinase (NTRK) inhibitor Vitrakvi (larotrectinib) has passed the drug committee (DCs) of general hospitals in Korea including the Seoul National University Hospital.

Thus, Vitrakvi's prescription is expected to start in earnest when Bayer reaches an agreement with the National Health Insurance Service in the ongoing pricing negotiations.

Vitrakvi, which was approved in May last year, is going through the reimbursement listing application process through the pharmacoeconomic evaluation exemption system. In No